Pulsatile administration of the epidermal growth factor receptor inhibitor Gefitinib is significantly more effective than continuous dosing for sensitizing tumors to paclitaxel
- Author
- SOLIT, David B1 2 ; YUHONG SHE2 ; LOBO, Jose2 ; KRIS, Mark G1 ; SCHER, Howard I1 ; ROSEN, Neal1 2 ; SIROTNAK, Frank M2
[1] Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York, United States
[2] Department of Molecular Pharmacology and Chemistry, Memorial Sloan-Kettering Cancer Center, New York, New York, United States - Source
Clinical cancer research. 2005, Vol 11, Num 5, pp 1983-1989, 7 p ; ref : 29 ref
- ISSN
- 1078-0432
- Scientific domain
- Medical oncology; Pharmacology drugs
- Publisher
- American Association for Cancer Research, Philadelphia, PA
- Publication country
- United States
- Document type
- Article
- Language
- English
- Keyword (fr)
- Anticancéreux Efficacité Géfitinib Paclitaxel Posologie Pulsatile Récepteur facteur croissance épiderme Récepteur facteur croissance Tumeur maligne Récepteur EGFR Antimitotique Enzyme Inhibiteur enzyme Protein-tyrosine kinase Taxane dérivé Transferases
- Keyword (en)
- Antineoplastic agent Efficiency Gefitinib Paclitaxel Posology Pulsatile Epidermal growth factor receptor Growth factor receptor Malignant tumor Epidermal growth factor receptor Antimitotic Enzyme Enzyme inhibitor Protein-tyrosine kinase Taxane derivatives Transferases
- Keyword (es)
- Anticanceroso Eficacia Gefitinib Paclitaxel Posología Pulsátil Receptor factor crecimiento epidermi Receptor factor crecimiento Tumor maligno Receptor EGFR Antimitótico Enzima Inhibidor enzima Protein-tyrosine kinase Taxane derivado Transferases
- Classification
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B02 Pharmacology. Drug treatments / 002B02R Antineoplastic agents
- Discipline
- Pharmacological treatments
- Origin
- Inist-CNRS
- Database
- PASCAL
- INIST identifier
- 16577769
Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS
Access to the document
Install on your browser
DOI
10.1158/1078-0432.CCR-04-1347 
https://dx.doi.org/10.1158/1078-0432.CCR-04-1347
"O:13:\"PanistOpenUrl\":36:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000idc\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:29:\"10.1158\/1078-0432.CCR-04-1347\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:176:\"Pulsatile administration of the epidermal growth factor receptor inhibitor Gefitinib is significantly more effective than continuous dosing for sensitizing tumors to paclitaxel\";s:9:\"\u0000*\u0000jtitle\";s:24:\"Clinical cancer research\";s:9:\"\u0000*\u0000stitle\";s:16:\"Clin. cancer res\";s:7:\"\u0000*\u0000date\";s:4:\"2005\";s:9:\"\u0000*\u0000volume\";s:2:\"11\";s:8:\"\u0000*\u0000issue\";s:1:\"5\";s:8:\"\u0000*\u0000spage\";s:4:\"1983\";s:8:\"\u0000*\u0000epage\";s:4:\"1989\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"1078-0432\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:5:\"SOLIT\";s:10:\"\u0000*\u0000aufirst\";s:7:\"David B\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:6:{i:0;s:10:\"YUHONG SHE\";i:1;s:10:\"LOBO, Jose\";i:2;s:12:\"KRIS, Mark G\";i:3;s:15:\"SCHER, Howard I\";i:4;s:11:\"ROSEN, Neal\";i:5;s:17:\"SIROTNAK, Frank M\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:176:\"Pulsatile administration of the epidermal growth factor receptor inhibitor Gefitinib is significantly more effective than continuous dosing for sensitizing tumors to paclitaxel\";s:8:\"\u0000*\u0000place\";s:16:\"Philadelphia, PA\";s:6:\"\u0000*\u0000pub\";s:40:\"American Association for Cancer Research\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"7\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Panist access
"O:12:\"IstexOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:29:\"10.1158\/1078-0432.CCR-04-1347\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:176:\"Pulsatile administration of the epidermal growth factor receptor inhibitor Gefitinib is significantly more effective than continuous dosing for sensitizing tumors to paclitaxel\";s:9:\"\u0000*\u0000jtitle\";s:24:\"Clinical cancer research\";s:9:\"\u0000*\u0000stitle\";s:16:\"Clin. cancer res\";s:7:\"\u0000*\u0000date\";s:4:\"2005\";s:9:\"\u0000*\u0000volume\";s:2:\"11\";s:8:\"\u0000*\u0000issue\";s:1:\"5\";s:8:\"\u0000*\u0000spage\";s:4:\"1983\";s:8:\"\u0000*\u0000epage\";s:4:\"1989\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"1078-0432\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:5:\"SOLIT\";s:10:\"\u0000*\u0000aufirst\";s:7:\"David B\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:6:{i:0;s:10:\"YUHONG SHE\";i:1;s:10:\"LOBO, Jose\";i:2;s:12:\"KRIS, Mark G\";i:3;s:15:\"SCHER, Howard I\";i:4;s:11:\"ROSEN, Neal\";i:5;s:17:\"SIROTNAK, Frank M\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:176:\"Pulsatile administration of the epidermal growth factor receptor inhibitor Gefitinib is significantly more effective than continuous dosing for sensitizing tumors to paclitaxel\";s:8:\"\u0000*\u0000place\";s:16:\"Philadelphia, PA\";s:6:\"\u0000*\u0000pub\";s:40:\"American Association for Cancer Research\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"7\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Istex access
"O:16:\"UnpaywallOpenUrl\":35:{s:8:\"\u0000*\u0000email\";s:27:\"assistance-portail@inist.fr\";s:6:\"\u0000*\u0000fmt\";N;s:6:\"\u0000*\u0000doi\";s:29:\"10.1158\/1078-0432.CCR-04-1347\";s:6:\"\u0000*\u0000pii\";N;s:7:\"\u0000*\u0000pmid\";N;s:9:\"\u0000*\u0000atitle\";N;s:9:\"\u0000*\u0000jtitle\";N;s:9:\"\u0000*\u0000stitle\";N;s:7:\"\u0000*\u0000date\";N;s:9:\"\u0000*\u0000volume\";N;s:8:\"\u0000*\u0000issue\";N;s:8:\"\u0000*\u0000spage\";N;s:8:\"\u0000*\u0000epage\";N;s:8:\"\u0000*\u0000pages\";N;s:7:\"\u0000*\u0000issn\";N;s:8:\"\u0000*\u0000eissn\";N;s:9:\"\u0000*\u0000aulast\";N;s:10:\"\u0000*\u0000aufirst\";N;s:9:\"\u0000*\u0000auinit\";N;s:10:\"\u0000*\u0000auinitm\";N;s:5:\"\u0000*\u0000au\";N;s:9:\"\u0000*\u0000aucorp\";N;s:7:\"\u0000*\u0000isbn\";N;s:8:\"\u0000*\u0000coden\";N;s:8:\"\u0000*\u0000genre\";N;s:7:\"\u0000*\u0000part\";N;s:9:\"\u0000*\u0000btitle\";N;s:8:\"\u0000*\u0000title\";N;s:8:\"\u0000*\u0000place\";N;s:6:\"\u0000*\u0000pub\";N;s:10:\"\u0000*\u0000edition\";N;s:9:\"\u0000*\u0000tpages\";N;s:9:\"\u0000*\u0000series\";N;s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";N;}"
Unpaywall access
"O:16:\"EuropePMCOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:29:\"10.1158\/1078-0432.CCR-04-1347\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:176:\"Pulsatile administration of the epidermal growth factor receptor inhibitor Gefitinib is significantly more effective than continuous dosing for sensitizing tumors to paclitaxel\";s:9:\"\u0000*\u0000jtitle\";s:24:\"Clinical cancer research\";s:9:\"\u0000*\u0000stitle\";s:16:\"Clin. cancer res\";s:7:\"\u0000*\u0000date\";s:4:\"2005\";s:9:\"\u0000*\u0000volume\";s:2:\"11\";s:8:\"\u0000*\u0000issue\";s:1:\"5\";s:8:\"\u0000*\u0000spage\";s:4:\"1983\";s:8:\"\u0000*\u0000epage\";s:4:\"1989\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"1078-0432\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:5:\"SOLIT\";s:10:\"\u0000*\u0000aufirst\";s:7:\"David B\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:6:{i:0;s:10:\"YUHONG SHE\";i:1;s:10:\"LOBO, Jose\";i:2;s:12:\"KRIS, Mark G\";i:3;s:15:\"SCHER, Howard I\";i:4;s:11:\"ROSEN, Neal\";i:5;s:17:\"SIROTNAK, Frank M\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:176:\"Pulsatile administration of the epidermal growth factor receptor inhibitor Gefitinib is significantly more effective than continuous dosing for sensitizing tumors to paclitaxel\";s:8:\"\u0000*\u0000place\";s:16:\"Philadelphia, PA\";s:6:\"\u0000*\u0000pub\";s:40:\"American Association for Cancer Research\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"7\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Europe PubMed Central access
"O:11:\"BaseOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:29:\"10.1158\/1078-0432.CCR-04-1347\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:176:\"Pulsatile administration of the epidermal growth factor receptor inhibitor Gefitinib is significantly more effective than continuous dosing for sensitizing tumors to paclitaxel\";s:9:\"\u0000*\u0000jtitle\";s:24:\"Clinical cancer research\";s:9:\"\u0000*\u0000stitle\";s:16:\"Clin. cancer res\";s:7:\"\u0000*\u0000date\";s:4:\"2005\";s:9:\"\u0000*\u0000volume\";s:2:\"11\";s:8:\"\u0000*\u0000issue\";s:1:\"5\";s:8:\"\u0000*\u0000spage\";s:4:\"1983\";s:8:\"\u0000*\u0000epage\";s:4:\"1989\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"1078-0432\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:5:\"SOLIT\";s:10:\"\u0000*\u0000aufirst\";s:7:\"David B\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:6:{i:0;s:10:\"YUHONG SHE\";i:1;s:10:\"LOBO, Jose\";i:2;s:12:\"KRIS, Mark G\";i:3;s:15:\"SCHER, Howard I\";i:4;s:11:\"ROSEN, Neal\";i:5;s:17:\"SIROTNAK, Frank M\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:176:\"Pulsatile administration of the epidermal growth factor receptor inhibitor Gefitinib is significantly more effective than continuous dosing for sensitizing tumors to paclitaxel\";s:8:\"\u0000*\u0000place\";s:16:\"Philadelphia, PA\";s:6:\"\u0000*\u0000pub\";s:40:\"American Association for Cancer Research\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"7\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Base Search access
"O:12:\"ArXivOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:29:\"10.1158\/1078-0432.CCR-04-1347\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:176:\"Pulsatile administration of the epidermal growth factor receptor inhibitor Gefitinib is significantly more effective than continuous dosing for sensitizing tumors to paclitaxel\";s:9:\"\u0000*\u0000jtitle\";s:24:\"Clinical cancer research\";s:9:\"\u0000*\u0000stitle\";s:16:\"Clin. cancer res\";s:7:\"\u0000*\u0000date\";s:4:\"2005\";s:9:\"\u0000*\u0000volume\";s:2:\"11\";s:8:\"\u0000*\u0000issue\";s:1:\"5\";s:8:\"\u0000*\u0000spage\";s:4:\"1983\";s:8:\"\u0000*\u0000epage\";s:4:\"1989\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"1078-0432\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:5:\"SOLIT\";s:10:\"\u0000*\u0000aufirst\";s:7:\"David B\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:6:{i:0;s:10:\"YUHONG SHE\";i:1;s:10:\"LOBO, Jose\";i:2;s:12:\"KRIS, Mark G\";i:3;s:15:\"SCHER, Howard I\";i:4;s:11:\"ROSEN, Neal\";i:5;s:17:\"SIROTNAK, Frank M\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:176:\"Pulsatile administration of the epidermal growth factor receptor inhibitor Gefitinib is significantly more effective than continuous dosing for sensitizing tumors to paclitaxel\";s:8:\"\u0000*\u0000place\";s:16:\"Philadelphia, PA\";s:6:\"\u0000*\u0000pub\";s:40:\"American Association for Cancer Research\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"7\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
arXiv access
